Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
Evaluate the Efficacy and Safety of R-CHOP-MTX±Zanubrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Central Nervous System Involvement, and Explore the Efficacy Indicators of CSF-ctDNA.
Diffuse Large B Cell Lymphoma (DLBCL)
DRUG: R-CHOP+Z+MTX|DRUG: R-CHOP+MTX
CSF-ctDNA negativity rate at the end of induction therapy (EOT), At the end of induction therapy (EOT), an average of 6 months
Progression Free Survival（PFS）, 2 years|Complete Response Rate（CR）, End of treatment visit (after last dose of Cycle 7 [Cycle length=21 days]）|Overall Survival（OS）, up to approximately 24 months|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), From enrollment to study completion, a maximum of 24 months
Evaluate the Efficacy and Safety of R-CHOP-MTX±Zanubrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Central Nervous System Involvement, and Explore the Efficacy Indicators of CSF-ctDNA.